{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:56:08Z","timestamp":1792454168765,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40261-024-01376-w","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T10:02:49Z","timestamp":1719482569000},"page":"527-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9207-4434","authenticated-orcid":false,"given":"Masaki","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiroh","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"1","key":"1376_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","volume":"25","author":"P Ljungman","year":"2011","unstructured":"Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151\u201369. https:\/\/doi.org\/10.1016\/j.hoc.2010.11.011.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"1376_CR2","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/s2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119\u201327. https:\/\/doi.org\/10.1016\/s2352-3026(15)00289-6.","journal-title":"Lancet Haematol."},{"issue":"9","key":"1376_CR3","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/ajt.15515","volume":"19","author":"E Gim\u00e9nez","year":"2019","unstructured":"Gim\u00e9nez E, Torres I, Albert E, Pi\u00f1ana JL, Hern\u00e1ndez-Boluda JC, Solano C, et al. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis. Am J Transplant. 2019;19(9):2479\u201394. https:\/\/doi.org\/10.1111\/ajt.15515.","journal-title":"Am J Transplant"},{"issue":"11","key":"1376_CR4","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/ijms20112666","volume":"20","author":"SY Cho","year":"2019","unstructured":"Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019;20(11):2666. https:\/\/doi.org\/10.3390\/ijms20112666.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1376_CR5","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"K Takenaka","year":"2015","unstructured":"Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who durvived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant. 2015;21(11):2008\u201316. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.019.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"1376_CR6","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","volume":"122","author":"M Schmidt-Hieber","year":"2013","unstructured":"Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122(19):3359\u201364. https:\/\/doi.org\/10.1182\/blood-2013-05-499830.","journal-title":"Blood"},{"issue":"20","key":"1376_CR7","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427\u201338. https:\/\/doi.org\/10.1182\/blood-2015-11-679639.","journal-title":"Blood"},{"issue":"3","key":"1376_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","volume":"118","author":"JM Goodrich","year":"1993","unstructured":"Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173\u20138. https:\/\/doi.org\/10.7326\/0003-4819-118-3-199302010-00003.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1376_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","volume":"118","author":"DJ Winston","year":"1993","unstructured":"Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118(3):179\u201384. https:\/\/doi.org\/10.7326\/0003-4819-118-3-199302010-00004.","journal-title":"Ann Intern Med"},{"issue":"19","key":"1376_CR10","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2019000956","volume":"135","author":"H Einsele","year":"2020","unstructured":"Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135(19):1619\u201329. https:\/\/doi.org\/10.1182\/blood.2019000956.","journal-title":"Blood"},{"issue":"11","key":"1376_CR11","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","volume":"18","author":"ML Green","year":"2012","unstructured":"Green ML, Leisenring W, Stachel D, Pergam SA, Sandmaier BM, Wald A, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1687\u201399. https:\/\/doi.org\/10.1016\/j.bbmt.2012.05.015.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"1376_CR12","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/s1473-3099(19)30107-0la","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260\u201372. https:\/\/doi.org\/10.1016\/s1473-3099(19)30107-0la.","journal-title":"Lancet Infect Dis"},{"issue":"20","key":"1376_CR13","doi-asserted-by":"publisher","first-page":"10884","DOI":"10.1128\/jvi.05265-11","volume":"85","author":"T Goldner","year":"2011","unstructured":"Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884\u201393. https:\/\/doi.org\/10.1128\/jvi.05265-11.","journal-title":"J Virol"},{"issue":"25","key":"1376_CR14","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1706640.","journal-title":"N Engl J Med"},{"issue":"6","key":"1376_CR15","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/ajt.15764","volume":"20","author":"FM Marty","year":"2020","unstructured":"Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703\u201311. https:\/\/doi.org\/10.1111\/ajt.15764.","journal-title":"Am J Transplant"},{"issue":"7","key":"1376_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13866","volume":"34","author":"A Anderson","year":"2020","unstructured":"Anderson A, Raja M, Vazquez N, Morris M, Komanduri K, Camargo J. Clinical, \u201creal-world\u201d experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transplant. 2020;34(7): e13866. https:\/\/doi.org\/10.1111\/ctr.13866.","journal-title":"Clin Transplant"},{"issue":"8","key":"1376_CR17","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","volume":"100","author":"P Derigs","year":"2021","unstructured":"Derigs P, Radujkovic A, Schubert ML, Schnitzler P, Sch\u00f6ning T, M\u00fcller-Tidow C, et al. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Ann Hematol. 2021;100(8):2087\u201393. https:\/\/doi.org\/10.1007\/s00277-020-04362-2.","journal-title":"Ann Hematol"},{"issue":"10","key":"1376_CR18","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","volume":"26","author":"JJ Johnsrud","year":"2020","unstructured":"Johnsrud JJ, Nguyen IT, Domingo W, Narasimhan B, Efron B, Brown JW. Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant. Biol Blood Marrow Transplant. 2020;26(10):1963\u201370. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.002.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"1376_CR19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/cid\/ciab298","volume":"73","author":"J Sassine","year":"2021","unstructured":"Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era. Clin Infect Dis. 2021;73(8):1346\u201354. https:\/\/doi.org\/10.1093\/cid\/ciab298.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1376_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41409-019-0730-y","volume":"55","author":"P Sharma","year":"2020","unstructured":"Sharma P, Gakhar N, MacDonald J, Abidi MZ, Benamu E, Bajrovic V, et al. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020;55(4):780\u20136. https:\/\/doi.org\/10.1038\/s41409-019-0730-y.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1376_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac687","volume":"10","author":"A Vyas","year":"2023","unstructured":"Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open Forum Infect Dis. 2023;10(1): ofac687. https:\/\/doi.org\/10.1093\/ofid\/ofac687.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1376_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","volume":"78","author":"ES Kim","year":"2018","unstructured":"Kim ES. Letermovir: first global approval. Drugs. 2018;78(1):147\u201352. https:\/\/doi.org\/10.1007\/s40265-017-0860-8.","journal-title":"Drugs"},{"key":"1376_CR23","unstructured":"MSD K.K., Tokyo, Japan. Prevymis\u00ae (letermovir) tablet 240mg, anti-cytomegalovirus chemotherapeutic agent. Pharmaceutical interview form. Revised May 2024, 10th edition [in Japanese]. Available from: https:\/\/www.msdconnect.jp\/wp-content\/uploads\/sites\/5\/2024\/05\/if_prevymis_tab.pdf . [Accessed 6 Jun 2024]."},{"key":"1376_CR24","unstructured":"Japanese Society for Transplantation and Cellular Therapy. Prevention and treatment of viral infections: cytomegalovirus infection, 5th edition (June 2022) [in Japanese]. Available from: https:\/\/www.jstct.or.jp\/uploads\/files\/guideline\/01_03_01_cmv05.pdf. [Accessed 3 Nov 2023]."},{"issue":"5","key":"1376_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jtct.2021.01.024","volume":"27","author":"AL Olson","year":"2021","unstructured":"Olson AL, Politikos I, Brunstein C, Milano F, Barker J, Hill JA. Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation. Transplant Cell Ther. 2021;27(5):359\u201362. https:\/\/doi.org\/10.1016\/j.jtct.2021.01.024.","journal-title":"Transplant Cell Ther."},{"issue":"6","key":"1376_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13904","volume":"24","author":"K Mizuno","year":"2022","unstructured":"Mizuno K, Sakurai M, Kato J, Yamaguchi K, Abe R, Koda Y, et al. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2022;24(6): e13904. https:\/\/doi.org\/10.1111\/tid.13904.","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"1376_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","volume":"56","author":"Y Mori","year":"2021","unstructured":"Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant. 2021;56(4):853\u201362. https:\/\/doi.org\/10.1038\/s41409-020-01082-z.","journal-title":"Bone Marrow Transplant"},{"key":"1376_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.666774","volume":"11","author":"T Terao","year":"2021","unstructured":"Terao T, Matsuoka KI, Narita K, Tsushima T, Yuyama S, Kuzume A, et al. Letermovir administration to prevent cytomegalovirus reactivation is the potential risk of chronic graft-versus-host disease in patients who received haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Front Oncol. 2021;11: 666774. https:\/\/doi.org\/10.3389\/fonc.2021.666774.","journal-title":"Front Oncol"},{"issue":"9","key":"1376_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jiac.2022.05.019","volume":"28","author":"H Yoshimura","year":"2022","unstructured":"Yoshimura H, Satake A, Ishii Y, Ichikawa J, Saito R, Konishi A, et al. Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis. J Infect Chemother. 2022;28(9):1317\u201323. https:\/\/doi.org\/10.1016\/j.jiac.2022.05.019.","journal-title":"J Infect Chemother"},{"issue":"12","key":"1376_CR30","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40261-021-01096-5","volume":"41","author":"I Hiraishi","year":"2021","unstructured":"Hiraishi I, Ueno R, Watanabe A, Maekawa S. Safety and effectiveness of letermovir in allogenic hematopoietic stem cell transplantation recipients: interim report of post-marketing surveillance in Japan. Clin Drug Investig. 2021;41(12):1075\u201386. https:\/\/doi.org\/10.1007\/s40261-021-01096-5.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1376_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103(1):3\u201310. https:\/\/doi.org\/10.1007\/s12185-015-1894-x.","journal-title":"Int J Hematol"},{"issue":"11","key":"1376_CR32","first-page":"1462","volume":"48","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. The unification of hematopoietic stem cell transplantation registry in Japan and establishment of the TRUMP system [In Japanese]. Rinsho Ketsueki. 2007;48(11):1462\u20139.","journal-title":"Rinsho Ketsueki"},{"key":"1376_CR33","unstructured":"Transplant Registry Unified Management Program (TRUMP). Available from: http:\/\/www.jdchct.or.jp\/trump\/. [Accessed 6 Jun 2024]."},{"key":"1376_CR34","unstructured":"MSD K.K., Tokyo, Japan. Prevymis\u00ae (letermovir) tablets 240mg, intravenous infusion 240mg. Pharmaceutical risk management plan [in Japanese]. Available from: https:\/\/www.msdconnect.jp\/wp-content\/uploads\/sites\/5\/2021\/02\/rmp_prevymis.pdf. [Accessed 6 Jun 2024]."},{"key":"1376_CR35","unstructured":"MSD K.K., Tokyo, Japan. Prevymis\u00ae (letermovir) tablets 240mg, anti-cytomegalovirus chemotherapeutic agent. Prescribing information. Revised January 2022, 2nd edition [in Japanese. Available from: https:\/\/www.msdconnect.jp\/wp-content\/uploads\/sites\/5\/2022\/01\/pi_prevymis_tab.pdf. [Accessed 6 Jun 2024]."},{"key":"1376_CR36","unstructured":"MSD K.K., Tokyo, Japan. Prevymis\u00ae (letermovir) intravenous infusion 240mg, anti-cytomegalovirus chemotherapeutic agent. Prescribing information. Revised May 2024, 4th edition [in Japanese]. Available from: https:\/\/www.msdconnect.jp\/wp-content\/uploads\/sites\/5\/2024\/05\/pi_prevymis_tab.pdf. [Accessed 6 Jun 2024]."},{"key":"1376_CR37","unstructured":"Extension of letermovir (LET) from day 100 to day 200 post-transplant for the prevention of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) participants (MK-8228-040), study results. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03930615. [Accessed 6 Jun 2024]."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01376-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01376-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01376-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:18:11Z","timestamp":1721794691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01376-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01376-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"10 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PMS and publication of this article were funded by MSD K.K., Tokyo, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Masaki Fukuda, Junko Hattori, Rika Ohkubo, Asuka Watanabe, and Shinichiroh Maekawa are employees of MSD K.K., Tokyo, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This survey was carried out in accordance with Good Post-Marketing Study Practice for Drugs as specified by the Ministry of Health, Labour and Welfare in Japan. The research protocol was approved by the Japan Conference of Clinical Research Institution Review Board (approval date 21 January, 2021).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was not required for this PMS in accordance with Good Post-Marketing Study Practice in Japan. Informed consent was obtained voluntarily at some facilities. All facilities agreed with the use of the survey data under a contract\/agreement with MSD K.K., Tokyo, Japan.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data sharing policy, including restrictions, of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA is available at . Requests for access to the study data can be submitted through the Engage Zone site or via e-mail to the Data Access mailbox (dataaccess@merck.com).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors met ICMJE authorship criteria; their specific contributions are as follows: conceptualization: all authors; data curation: AW, SM; formal analysis: AW, SM; investigation: all authors; methodology: AW, SM; project administration: MF; supervision: MF; validation: AW, SM; visualization: MF, JH, RO; writing: original draft: MF, JH, RO; writing: review and editing: all authors. All authors approved the final version of this manuscript and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}